Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook



 

US approves modified-virus cancer treatment

02 November 2015

By Arit Udoh

Appeared in BioNews 826

The US Food and Drug Administration has approved a drug derived from a genetically modified herpes virus for the treatment of melanoma that cannot be removed by surgery.

Imylgic (chemical name talimogene laherparepvec), manufactured by Amgen, is the first oncolytic viral therapy to receive regulatory approval.

The drug works by invading and replicating within cancer cells, eventually causing them to burst – a natural ability of the herpes virus.

But the modified virus also carries with it a gene fragment encoding a protein called granulocyte-macrophage colony stimulating factor (GM-CSF). When produced by the virus, this stimulates the patient's immune system to recognise and destroy cancer cells.

The modified virus is also able to travel in the patient's bloodstream and infect other tumour cells. It can also enter healthy cells but is unable to replicate within them, thus sparing them.

Imlygic's approval follows the outcome of a multicentre, randomised, phase 3 clinical trial involving 436 patients. Patients in the study were treated over a six-month period with either Imlygic or GM-CSF injected directly into the melanoma lesions.

The study showed a reduction in lymph node lesion size in 16.3 percent of the patients treated with Imlygic compared to 2.1 percent in the GM-CSF arm. The effect of the drug and overall survival was largest in patients with unresectable melanoma that had not spread beyond the skin and lymph nodes.

But the study showed the drug had no benefit for patients with melanoma that had spread to the brain, lungs and other internal organs.

The European Medicines Agency has also recommended the drug for approval, setting the stage for marketing authorisation in Europe.

Melanoma is an aggressive form of skin cancer and a leading cause of death from skin disease. Ultraviolet light and unprotected sun exposure are the main risk factors. When detected early, melanoma can be removed surgically but the prognosis is poor for the more advanced stage of the disease, particularly when cancer cells have metastasized to other parts of the body.

'As an oncolytic viral therapy, Imlygic has a unique approach, and provides another option for treating eligible patients with unresectable disease that has recurred after initial surgery' said Professor Howard Kaufman, from the Rutgers Cancer Institute of New Jersey, principal investigator in the Imlygic trial.

There are at least six biotechs and research groups working on oncolytic viruses and about a dozen clinical trials currently ongoing, meaning Imlygic may be the first of many to emerge.

'The era of the oncolytic virus is probably here,' Dr Stephen Russell, a specialist from the Mayo Clinic in Rochester, Minnesota told Nature News. 'I expect to see a great deal happening over the next few years.'

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

30 November 2015 - by Dr Jane Currie 
Scientists have used genome-editing technology to identify a core set of 1580 genes that are essential to human life...
16 November 2015 - by Meetal Solanki 
Researchers in the USA have mapped the sequence of genetic changes from early skin lesions, such as common moles, to malignant skin cancer...

13 April 2015 - by Dr Nicoletta Charolidi 
A new type of cancer vaccine that enriches the immune system with tailor-made anti-tumour antibodies has shown early signs of promise...
22 September 2014 - by Dr Lanay Griessner 
A skin cancer drug designed to be effective in patients whose cancer is driven by a specific gene mutation has been recommended by the National Institute for Health and Care Excellence to treat patients with advanced melanoma...
05 November 2012 - by Maria Sheppard 
A drug which prolongs life in a form of skin cancer associated with a genetic mutation has been recommended for use on the NHS...
11 June 2012 - by Dr Tamara Hirsch 
Two drugs targeting advanced melanoma linked to a mutation in the BRAF gene are more effective than current chemotherapy at slowing the progress of the skin cancer, clinical trial results indicate...
28 May 2012 - by James Brooks 
A drug that mimics broken strands of DNA and pushes treatment-resistant cancer cells to autodestruct has produced encouraging results in a first clinical trial. The medicine, DT01, is the forerunner for a new class of drug developed by researchers at the Institut Curie in Paris...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation